Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flufenamic Acid for Hospitalised Influenza
NCT03238612Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jan 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Flufenamic acid in Influenza A (IAV) and pneumonia (2 arms), sponsored by The University of Hong Kong. Primary endpoint: Mortality at 30 days. Status: unknown.
02
Drugs
Flufenamic acid
03
Conditions
Influenza A (IAV)pneumonia
Beyond the preview
Go deeper on NCT03238612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238612.